CORONAVIRUS/Taiwan-developed drug to be tested on severe COVID-19 cases in U.S.
Taipei, June 4 (CNA) A drug candidate developed by a Taiwanese company for the treatment of COVID-19 will be administered to seriously ill patients in its Phase II clinical trials in the United States, pending authorization by the relevant authorities, according to the developer Golden Biotechnology Corp.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
- Taiwan reports 43,085 new COVID-19 cases, 48 deathsTaiwan on Saturday reported 43,085 new COVID-19 infections, including 45 imported cases, and 48 deaths from the disease, according to the Central Epidemic Command Center (CECC).10/01/2022 03:20 PM
- Taiwan drops vaccination requirement for outbound tour groupsTaiwan's Tourism Bureau on Friday rescinded a rule that required members of outbound tour groups receive three shots of COVID-19 vaccines before they can travel abroad.10/01/2022 03:11 PM
- Taiwan mulls easing restrictions related to COVID-19 patientsTaiwan's government is considering easing restrictions on individuals infected with COVID-19 by shortening a seven-day health monitoring period and allowing them to dine out ...09/30/2022 08:56 PM
First German parliamentary group since COVID-19 arrives in Taiwan10/02/2022 11:48 AM
Hot, dry weather forecast for Sunday as autumn heatwave continues10/02/2022 10:48 AM
Taiwan headline news10/02/2022 10:15 AM
Taiwanese player wins South Korean go-kart racing title10/01/2022 09:51 PM
Taichung Commercial Bank board agrees to acquire American bank10/01/2022 09:49 PM